Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB CAR-NK019 in Refractory/Relapsed B-cell NHL
NCT05472558Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2022
- Primary completion
- Dec 2025
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR-NK019 in B-cell non-Hodgkin lymphoma, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jul 2022; status: recruiting.
02
Drugs
CAR-NK019
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05472558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05472558.